Effects of glatiramer acetate on tissue damage, cortical functions and fatigue in multiple sclerosis: a morpho-functional mri study.

Treatment tested

• Glatiramer acetate

  Unknown

Inclusion: Inclusion criteria: - Age between 18 and 60 years; - Diagnosis of multiple sclerosis, according to the revised McDonald criteria [37]; - Relapsing-remitting or benign course; - EDSS score between 0.0 and 5.5 [38]; - For BMS: disease duration of 15 years or longer, EDSS <3.0 Exclusion: Exclusion criteria: - Relapse or corticosteroid treatment within 30 days before study entry, - Chronic use of psychotropic drugs - Use of other disease-modifying treatments in the previous six months - Clinically significant systemic diseases.

Against this background, the present case-control group study has been designed with the aim to evaluate the impact of Glatiramer Acetate treatment on Multiple Sclerosis-related fatigue, under both a clinical and a paraclinical point of view.